nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—AGTR1—dilated cardiomyopathy	0.798	1	CbGaD
Valsartan—ALB—Furosemide—dilated cardiomyopathy	0.0345	1	CbGbCtD
Valsartan—CYP2C9—cardial valve—dilated cardiomyopathy	0.0114	0.59	CbGeAlD
Valsartan—Dry cough—Lisinopril—dilated cardiomyopathy	0.00698	0.0677	CcSEcCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—MAS1—dilated cardiomyopathy	0.00486	0.136	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—NR3C2—dilated cardiomyopathy	0.00378	0.106	CbGpPWpGaD
Valsartan—Tasosartan—AGTR2—dilated cardiomyopathy	0.00337	0.345	CrCbGaD
Valsartan—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00271	0.0263	CcSEcCtD
Valsartan—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.0026	0.0252	CcSEcCtD
Valsartan—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00208	0.0202	CcSEcCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—AGTR2—dilated cardiomyopathy	0.00204	0.0571	CbGpPWpGaD
Valsartan—AGTR1—cardiac ventricle—dilated cardiomyopathy	0.00199	0.103	CbGeAlD
Valsartan—Forasartan—AGTR1—dilated cardiomyopathy	0.00193	0.197	CrCbGaD
Valsartan—AGTR1—myocardium—dilated cardiomyopathy	0.00187	0.0969	CbGeAlD
Valsartan—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00176	0.017	CcSEcCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE—dilated cardiomyopathy	0.00174	0.0488	CbGpPWpGaD
Valsartan—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00173	0.0168	CcSEcCtD
Valsartan—Drug interaction—Furosemide—dilated cardiomyopathy	0.00155	0.015	CcSEcCtD
Valsartan—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00153	0.0148	CcSEcCtD
Valsartan—Vasculitis—Furosemide—dilated cardiomyopathy	0.00147	0.0143	CcSEcCtD
Valsartan—Renal failure—Spironolactone—dilated cardiomyopathy	0.00145	0.0141	CcSEcCtD
Valsartan—AGTR1—heart—dilated cardiomyopathy	0.0013	0.0677	CbGeAlD
Valsartan—Viral infection—Lisinopril—dilated cardiomyopathy	0.0012	0.0116	CcSEcCtD
Valsartan—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00119	0.0115	CcSEcCtD
Valsartan—Swelling—Furosemide—dilated cardiomyopathy	0.00118	0.0115	CcSEcCtD
Valsartan—Alopecia—Spironolactone—dilated cardiomyopathy	0.00117	0.0114	CcSEcCtD
Valsartan—Tasosartan—AGTR1—dilated cardiomyopathy	0.00117	0.12	CrCbGaD
Valsartan—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00116	0.0113	CcSEcCtD
Valsartan—AGTR1—cardiac atrium—dilated cardiomyopathy	0.00111	0.0579	CbGeAlD
Valsartan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00111	0.0108	CcSEcCtD
Valsartan—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00111	0.0107	CcSEcCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—AGT—dilated cardiomyopathy	0.0011	0.0309	CbGpPWpGaD
Valsartan—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00109	0.0106	CcSEcCtD
Valsartan—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00106	0.0103	CcSEcCtD
Valsartan—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00105	0.0102	CcSEcCtD
Valsartan—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00102	0.00988	CcSEcCtD
Valsartan—ALB—heart—dilated cardiomyopathy	0.00101	0.0522	CbGeAlD
Valsartan—Olmesartan—AGTR1—dilated cardiomyopathy	0.000988	0.101	CrCbGaD
Valsartan—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000979	0.00949	CcSEcCtD
Valsartan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000954	0.00925	CcSEcCtD
Valsartan—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000944	0.00915	CcSEcCtD
Valsartan—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000941	0.00912	CcSEcCtD
Valsartan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000924	0.00896	CcSEcCtD
Valsartan—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000922	0.00893	CcSEcCtD
Valsartan—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000893	0.00865	CcSEcCtD
Valsartan—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000849	0.00823	CcSEcCtD
Valsartan—Somnolence—Spironolactone—dilated cardiomyopathy	0.000839	0.00813	CcSEcCtD
Valsartan—AGTR1—Arf6 signaling events—ADRB2—dilated cardiomyopathy	0.000835	0.0234	CbGpPWpGaD
Valsartan—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000827	0.00802	CcSEcCtD
Valsartan—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000824	0.00799	CcSEcCtD
Valsartan—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000824	0.00798	CcSEcCtD
Valsartan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000815	0.0079	CcSEcCtD
Valsartan—Renal failure—Furosemide—dilated cardiomyopathy	0.000792	0.00767	CcSEcCtD
Valsartan—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000787	0.00763	CcSEcCtD
Valsartan—Irbesartan—AGTR1—dilated cardiomyopathy	0.000768	0.0786	CrCbGaD
Valsartan—Candesartan—AGTR1—dilated cardiomyopathy	0.000768	0.0786	CrCbGaD
Valsartan—Urticaria—Spironolactone—dilated cardiomyopathy	0.00075	0.00727	CcSEcCtD
Valsartan—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000734	0.00712	CcSEcCtD
Valsartan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000716	0.00694	CcSEcCtD
Valsartan—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000714	0.00692	CcSEcCtD
Valsartan—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000709	0.00687	CcSEcCtD
Valsartan—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000706	0.00684	CcSEcCtD
Valsartan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000695	0.00674	CcSEcCtD
Valsartan—Pruritus—Spironolactone—dilated cardiomyopathy	0.000668	0.00647	CcSEcCtD
Valsartan—AGTR1—Arf6 trafficking events—ADRB2—dilated cardiomyopathy	0.000659	0.0185	CbGpPWpGaD
Valsartan—Angiopathy—Furosemide—dilated cardiomyopathy	0.000656	0.00636	CcSEcCtD
Valsartan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000653	0.00633	CcSEcCtD
Valsartan—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000652	0.00632	CcSEcCtD
Valsartan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000646	0.00626	CcSEcCtD
Valsartan—AGTR1—Arf6 trafficking events—ITGB1—dilated cardiomyopathy	0.000637	0.0178	CbGpPWpGaD
Valsartan—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000634	0.00614	CcSEcCtD
Valsartan—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00063	0.0061	CcSEcCtD
Valsartan—Malnutrition—Furosemide—dilated cardiomyopathy	0.000629	0.0061	CcSEcCtD
Valsartan—AGTR1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000629	0.0176	CbGpPWpGaD
Valsartan—CYP2C9—heart—dilated cardiomyopathy	0.000628	0.0326	CbGeAlD
Valsartan—Dizziness—Spironolactone—dilated cardiomyopathy	0.000624	0.00605	CcSEcCtD
Valsartan—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000624	0.00605	CcSEcCtD
Valsartan—Flatulence—Furosemide—dilated cardiomyopathy	0.00062	0.00601	CcSEcCtD
Valsartan—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000618	0.00599	CcSEcCtD
Valsartan—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000616	0.00597	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ITGB1—dilated cardiomyopathy	0.000606	0.017	CbGpPWpGaD
Valsartan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000605	0.00586	CcSEcCtD
Valsartan—Vomiting—Spironolactone—dilated cardiomyopathy	0.0006	0.00582	CcSEcCtD
Valsartan—Rash—Spironolactone—dilated cardiomyopathy	0.000595	0.00577	CcSEcCtD
Valsartan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000595	0.00576	CcSEcCtD
Valsartan—Renal failure—Lisinopril—dilated cardiomyopathy	0.000594	0.00576	CcSEcCtD
Valsartan—Vision blurred—Furosemide—dilated cardiomyopathy	0.000593	0.00575	CcSEcCtD
Valsartan—Headache—Spironolactone—dilated cardiomyopathy	0.000591	0.00573	CcSEcCtD
Valsartan—AGTR1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000584	0.0164	CbGpPWpGaD
Valsartan—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00057	0.00552	CcSEcCtD
Valsartan—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000567	0.00549	CcSEcCtD
Valsartan—Vertigo—Furosemide—dilated cardiomyopathy	0.000565	0.00548	CcSEcCtD
Valsartan—Nausea—Spironolactone—dilated cardiomyopathy	0.000561	0.00543	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000551	0.0154	CbGpPWpGaD
Valsartan—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000544	0.00527	CcSEcCtD
Valsartan—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000542	0.00526	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RPS6KB1—dilated cardiomyopathy	0.000539	0.0151	CbGpPWpGaD
Valsartan—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000538	0.00522	CcSEcCtD
Valsartan—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000536	0.00519	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000532	0.00516	CcSEcCtD
Valsartan—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000532	0.00515	CcSEcCtD
Valsartan—Dry mouth—Furosemide—dilated cardiomyopathy	0.000524	0.00508	CcSEcCtD
Valsartan—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000514	0.00498	CcSEcCtD
Valsartan—Shock—Furosemide—dilated cardiomyopathy	0.000505	0.0049	CcSEcCtD
Valsartan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000504	0.00488	CcSEcCtD
Valsartan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000503	0.00487	CcSEcCtD
Valsartan—Skin disorder—Furosemide—dilated cardiomyopathy	0.000499	0.00484	CcSEcCtD
Valsartan—Losartan—AGTR1—dilated cardiomyopathy	0.000495	0.0506	CrCbGaD
Valsartan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000492	0.00477	CcSEcCtD
Valsartan—Anorexia—Furosemide—dilated cardiomyopathy	0.00049	0.00474	CcSEcCtD
Valsartan—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000489	0.00474	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RAC1—dilated cardiomyopathy	0.000487	0.0137	CbGpPWpGaD
Valsartan—Hypotension—Furosemide—dilated cardiomyopathy	0.00048	0.00465	CcSEcCtD
Valsartan—Alopecia—Lisinopril—dilated cardiomyopathy	0.000479	0.00465	CcSEcCtD
Valsartan—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000475	0.00461	CcSEcCtD
Valsartan—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000472	0.00458	CcSEcCtD
Valsartan—Flatulence—Lisinopril—dilated cardiomyopathy	0.000465	0.00451	CcSEcCtD
Valsartan—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000462	0.00448	CcSEcCtD
Valsartan—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000461	0.00447	CcSEcCtD
Valsartan—Back pain—Lisinopril—dilated cardiomyopathy	0.000457	0.00443	CcSEcCtD
Valsartan—Somnolence—Furosemide—dilated cardiomyopathy	0.000457	0.00443	CcSEcCtD
Valsartan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000454	0.0044	CcSEcCtD
Valsartan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000446	0.00433	CcSEcCtD
Valsartan—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000445	0.00431	CcSEcCtD
Valsartan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000443	0.0043	CcSEcCtD
Valsartan—Fatigue—Furosemide—dilated cardiomyopathy	0.000443	0.00429	CcSEcCtD
Valsartan—Constipation—Furosemide—dilated cardiomyopathy	0.000439	0.00426	CcSEcCtD
Valsartan—Angioedema—Lisinopril—dilated cardiomyopathy	0.000431	0.00418	CcSEcCtD
Valsartan—Vertigo—Lisinopril—dilated cardiomyopathy	0.000424	0.00411	CcSEcCtD
Valsartan—Syncope—Lisinopril—dilated cardiomyopathy	0.000423	0.0041	CcSEcCtD
Valsartan—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00042	0.00407	CcSEcCtD
Valsartan—Palpitations—Lisinopril—dilated cardiomyopathy	0.000417	0.00404	CcSEcCtD
Valsartan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000415	0.00402	CcSEcCtD
Valsartan—Cough—Lisinopril—dilated cardiomyopathy	0.000412	0.00399	CcSEcCtD
Valsartan—Urticaria—Furosemide—dilated cardiomyopathy	0.000408	0.00395	CcSEcCtD
Valsartan—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000406	0.00393	CcSEcCtD
Valsartan—Chest pain—Lisinopril—dilated cardiomyopathy	0.000402	0.0039	CcSEcCtD
Valsartan—Myalgia—Lisinopril—dilated cardiomyopathy	0.000402	0.0039	CcSEcCtD
Valsartan—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000402	0.0039	CcSEcCtD
Valsartan—Anxiety—Lisinopril—dilated cardiomyopathy	0.000401	0.00388	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000399	0.00387	CcSEcCtD
Valsartan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000393	0.00381	CcSEcCtD
Valsartan—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000385	0.00373	CcSEcCtD
Valsartan—Oedema—Lisinopril—dilated cardiomyopathy	0.000385	0.00373	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000384	0.0108	CbGpPWpGaD
Valsartan—Infection—Lisinopril—dilated cardiomyopathy	0.000383	0.00371	CcSEcCtD
Valsartan—Shock—Lisinopril—dilated cardiomyopathy	0.000379	0.00367	CcSEcCtD
Valsartan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000378	0.00367	CcSEcCtD
Valsartan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000377	0.00366	CcSEcCtD
Valsartan—ALB—Platelet degranulation—TTN—dilated cardiomyopathy	0.000377	0.0106	CbGpPWpGaD
Valsartan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000374	0.00363	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000372	0.0104	CbGpPWpGaD
Valsartan—Asthenia—Furosemide—dilated cardiomyopathy	0.000368	0.00357	CcSEcCtD
Valsartan—Anorexia—Lisinopril—dilated cardiomyopathy	0.000367	0.00356	CcSEcCtD
Valsartan—Pruritus—Furosemide—dilated cardiomyopathy	0.000363	0.00352	CcSEcCtD
Valsartan—Hypotension—Lisinopril—dilated cardiomyopathy	0.00036	0.00349	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TTN—dilated cardiomyopathy	0.000359	0.0101	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000357	0.01	CbGpPWpGaD
Valsartan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000351	0.00341	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000351	0.0034	CcSEcCtD
Valsartan—Insomnia—Lisinopril—dilated cardiomyopathy	0.000349	0.00338	CcSEcCtD
Valsartan—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000346	0.00335	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000345	0.00966	CbGpPWpGaD
Valsartan—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000344	0.00333	CcSEcCtD
Valsartan—Somnolence—Lisinopril—dilated cardiomyopathy	0.000343	0.00332	CcSEcCtD
Valsartan—Dizziness—Furosemide—dilated cardiomyopathy	0.00034	0.00329	CcSEcCtD
Valsartan—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000339	0.00329	CcSEcCtD
Valsartan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000335	0.00325	CcSEcCtD
Valsartan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000333	0.00322	CcSEcCtD
Valsartan—Fatigue—Lisinopril—dilated cardiomyopathy	0.000332	0.00322	CcSEcCtD
Valsartan—Constipation—Lisinopril—dilated cardiomyopathy	0.00033	0.00319	CcSEcCtD
Valsartan—ALB—Platelet degranulation—ACTN2—dilated cardiomyopathy	0.000327	0.00915	CbGpPWpGaD
Valsartan—Vomiting—Furosemide—dilated cardiomyopathy	0.000327	0.00316	CcSEcCtD
Valsartan—Rash—Furosemide—dilated cardiomyopathy	0.000324	0.00314	CcSEcCtD
Valsartan—Dermatitis—Furosemide—dilated cardiomyopathy	0.000324	0.00314	CcSEcCtD
Valsartan—Headache—Furosemide—dilated cardiomyopathy	0.000322	0.00312	CcSEcCtD
Valsartan—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000315	0.00305	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—ACTN2—dilated cardiomyopathy	0.000311	0.00872	CbGpPWpGaD
Valsartan—Urticaria—Lisinopril—dilated cardiomyopathy	0.000306	0.00297	CcSEcCtD
Valsartan—Nausea—Furosemide—dilated cardiomyopathy	0.000305	0.00296	CcSEcCtD
Valsartan—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000305	0.00295	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.000296	0.00828	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.000296	0.00828	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—EGFR—dilated cardiomyopathy	0.000295	0.00826	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000287	0.00803	CbGpPWpGaD
Valsartan—Losartan—ACE—dilated cardiomyopathy	0.000286	0.0293	CrCbGaD
Valsartan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000284	0.00275	CcSEcCtD
Valsartan—ALB—Platelet degranulation—VCL—dilated cardiomyopathy	0.000278	0.00778	CbGpPWpGaD
Valsartan—Asthenia—Lisinopril—dilated cardiomyopathy	0.000276	0.00268	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000275	0.0077	CbGpPWpGaD
Valsartan—Pruritus—Lisinopril—dilated cardiomyopathy	0.000273	0.00264	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000269	0.00755	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VCL—dilated cardiomyopathy	0.000265	0.00741	CbGpPWpGaD
Valsartan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000264	0.00256	CcSEcCtD
Valsartan—Dizziness—Lisinopril—dilated cardiomyopathy	0.000255	0.00247	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00025	0.007	CbGpPWpGaD
Valsartan—Vomiting—Lisinopril—dilated cardiomyopathy	0.000245	0.00237	CcSEcCtD
Valsartan—Rash—Lisinopril—dilated cardiomyopathy	0.000243	0.00235	CcSEcCtD
Valsartan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000243	0.00235	CcSEcCtD
Valsartan—Headache—Lisinopril—dilated cardiomyopathy	0.000241	0.00234	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000231	0.00649	CbGpPWpGaD
Valsartan—Nausea—Lisinopril—dilated cardiomyopathy	0.000229	0.00222	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000215	0.00603	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—dilated cardiomyopathy	0.000211	0.00591	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000208	0.00584	CbGpPWpGaD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—CD36—dilated cardiomyopathy	0.000203	0.00569	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000198	0.00556	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000198	0.00556	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000194	0.00544	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000193	0.0054	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000189	0.00529	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000189	0.00529	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000184	0.00517	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—SOD2—dilated cardiomyopathy	0.000183	0.00514	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000181	0.00507	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000179	0.005	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000176	0.00492	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000169	0.00473	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.000167	0.00468	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000162	0.00454	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00016	0.00448	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000151	0.00423	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000151	0.00423	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	0.000149	0.00418	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000146	0.0041	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000146	0.00408	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000145	0.00406	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.000145	0.00406	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000145	0.00405	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000143	0.004	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	0.000142	0.00399	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00014	0.00393	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000136	0.00381	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00013	0.00366	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ANKRD1—dilated cardiomyopathy	0.000128	0.00358	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000127	0.00356	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000127	0.00356	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.000123	0.00345	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TAZ—dilated cardiomyopathy	0.00012	0.00336	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	0.000119	0.00333	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000119	0.00332	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000118	0.00331	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	0.000113	0.00317	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000113	0.00317	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00011	0.00309	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00011	0.00308	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SDHA—dilated cardiomyopathy	0.000109	0.00304	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000107	0.00301	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000103	0.0029	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000101	0.00282	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	9.01e-05	0.00252	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TTN—dilated cardiomyopathy	8.61e-05	0.00241	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ANKRD1—dilated cardiomyopathy	8.58e-05	0.0024	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.53e-05	0.00239	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.53e-05	0.00239	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	8.47e-05	0.00237	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—AGT—dilated cardiomyopathy	8.17e-05	0.00229	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TAZ—dilated cardiomyopathy	8.06e-05	0.00226	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.93e-05	0.00222	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.75e-05	0.00217	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.75e-05	0.00217	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.68e-05	0.00215	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	7.47e-05	0.00209	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.45e-05	0.00209	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SDHA—dilated cardiomyopathy	7.29e-05	0.00204	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.25e-05	0.00203	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.25e-05	0.00203	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.21e-05	0.00202	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.98e-05	0.00196	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	6.96e-05	0.00195	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	6.9e-05	0.00193	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.74e-05	0.00189	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.62e-05	0.00185	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.45e-05	0.00181	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VCL—dilated cardiomyopathy	6.35e-05	0.00178	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.23e-05	0.00174	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.8e-05	0.00163	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	5.66e-05	0.00159	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.65e-05	0.00158	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	5.27e-05	0.00148	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.16e-05	0.00144	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	4.97e-05	0.00139	CbGpPWpGaD
Valsartan—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	4.9e-05	0.00137	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.83e-05	0.00135	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.62e-05	0.00129	CbGpPWpGaD
Valsartan—ALB—Metabolism—TAZ—dilated cardiomyopathy	4.61e-05	0.00129	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.58e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.58e-05	0.00128	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	4.5e-05	0.00126	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.45e-05	0.00125	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.39e-05	0.00123	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.33e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.26e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.19e-05	0.00118	CbGpPWpGaD
Valsartan—ALB—Metabolism—SDHA—dilated cardiomyopathy	4.17e-05	0.00117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.12e-05	0.00115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	4.01e-05	0.00112	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.9e-05	0.00109	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.83e-05	0.00107	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	3.77e-05	0.00106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	3.41e-05	0.000956	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.34e-05	0.000936	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	3.3e-05	0.000923	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	3.19e-05	0.000893	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX1—dilated cardiomyopathy	2.95e-05	0.000826	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.91e-05	0.000815	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CD36—dilated cardiomyopathy	2.87e-05	0.000805	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.87e-05	0.000804	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD36—dilated cardiomyopathy	2.72e-05	0.000762	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.59e-05	0.000727	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—dilated cardiomyopathy	2.59e-05	0.000724	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.57e-05	0.000721	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAC1—dilated cardiomyopathy	2.56e-05	0.000718	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.54e-05	0.000712	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.48e-05	0.000694	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.47e-05	0.000693	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.23e-05	0.000624	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.08e-05	0.000583	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.03e-05	0.000568	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2e-05	0.000559	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—dilated cardiomyopathy	1.98e-05	0.000555	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—dilated cardiomyopathy	1.93e-05	0.000541	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.82e-05	0.000511	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—dilated cardiomyopathy	1.74e-05	0.000487	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.72e-05	0.000482	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.7e-05	0.000476	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.47e-05	0.000412	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.18e-05	0.00033	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—dilated cardiomyopathy	1.13e-05	0.000317	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—dilated cardiomyopathy	1.1e-05	0.000309	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—dilated cardiomyopathy	9.92e-06	0.000278	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	9.26e-06	0.00026	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	9.02e-06	0.000253	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	8.12e-06	0.000228	CbGpPWpGaD
